Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments

mAbs

Volumn 5, Issue 2, 2013, Pages 288-296

  Hansen, Ryan J ^a   Brown, Robin M ^a   Lu, Jirong ^a   Wroblewski, Victor J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antibody; ELISA; Fab; Free ligand; PK PD

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; LIGAND;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INCUBATION TIME; PROCESS OPTIMIZATION;

ANTIBODY; ELISA; FAB; FREE LIGAND; PK/PD;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOGLOBULIN FAB FRAGMENTS; KINETICS; LIGANDS; RATS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84876554030     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.23508     Document Type: Article

References (16)

1. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68; PMID:15389672; http://dx.doi.org/10.1002/jps.20178
2. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-58; PMID:18784655; http://dx.doi.org/10.1038/clpt.2008.170
3. Yu J, Karcher H, Feire AL, Lowe PJ. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 2011; 13: 169-78; PMID:21336535; http://dx.doi.org/10.1208/s12248-011-9256-y
4. Davda JP, Hansen RJ. Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets. MAbs 2010; 2: 576-88; PMID:20676036; http://dx.doi.org/10. 4161/mabs.2.5.12833
5. Deng R, Jin F, Prabhu S, Iyer S. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? Expert Opin Drug Metab Toxicol 2012; 8: 141-60; PMID:22248267; http://dx.doi.org/10. 1517/1742525 5.2012.643868
6. Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 2011; 13: 99-110; PMID:21240643; http://dx.doi.org/10.1208/ s12248-011-9251-3
7. Adelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-9; PMID:10932067; http://dx.doi.org/10.1067/mai.2000.108310
8. Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, et al. Use of an anti- IgE humanized monoclonal antibody in ragweedinduced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110-21; PMID:9257795; http://dx.doi.org/10.1016/S0091-6749(97)70202-1
9. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63: 548-61; PMID:17096680; http://dx.doi.org/10.1111/j. 1365- 2125.2006.02803.x
10. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68: 61-76; PMID:19660004; http://dx.doi.org/10.1111/j.1365-2125.2009.03401.x
11. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 2010; 106: 195-209; PMID:20050847; http://dx.doi.org/10.1111/j.1742-7843.2009.00513.x
12. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan- Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J 2008; 10: 425-30; PMID:18686041; http://dx.doi.org/10.1208/ s12248-008-9045-4
13. Betts AM, Clark TH, Yang J, Treadway JL, Li M, Giovanelli MA, et al. The application of target information and preclinical pharmacokinetic/ pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther 2010; 333: 2-13; PMID:20089807; http://dx.doi.org/10.1124/jpet.109.164129
14. Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A 2009; 106: 9820-5; PMID:19443683; http://dx.doi.org/10.1073/pnas.0903849106
15. Ni YG, Di Marco S, Condra JH, Peterson LB, Wang W, Wang F, et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDLreceptor reduces LDL cholesterol in vivo. J Lipid Res 2011; 52: 78-86; PMID:20959675; http://dx.doi.org/10.1194/jlr.M011445
16. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26: 871-6; PMID:17031285; http://dx.doi.org/10.1097/ 01. iae.0000233327.68433.02